Drugs

Discovery paves way for development of new therapies for Chagas disease

Discovery paves way for development of new therapies for Chagas disease

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects some 8 million people worldwide. More than a third develop serious heart or digestive problems with an increased risk of death. The process that leads to this clinical condition is not completely understood. An article published in the journal Biomedicines describes a study by Brazilian …

Discovery paves way for development of new therapies for Chagas disease Read More »

Glowing Green Cells

Anti-aging drugs seek to eliminate ‘zombie’ cells – but could that be dangerous?

Senescent cells are distinguished by the fact that they eventually stop multiplying but do not die as expected. Senescent cells help heal damaged tissue According to a recent study from the University of California, San Francisco, not all senescent cells are harmful “zombies” that must be eliminated to avoid age-related diseases. Instead, some of them …

Anti-aging drugs seek to eliminate ‘zombie’ cells – but could that be dangerous? Read More »

A new family of adeno-associated viral vectors has been shown to be more efficient in delivering genetic cargo

A new family of adeno-associated viral vectors has been shown to be more efficient in delivering genetic cargo

Gene therapies can treat and even cure some genetic diseases, but it is difficult to deliver the treatments to the parts of the body where they are needed. The researchers engineered viruses called adeno-associated viruses (AAV) to deliver the cargo -; as a functional copy of a gene -; to specific cells and organs, but …

A new family of adeno-associated viral vectors has been shown to be more efficient in delivering genetic cargo Read More »

Ionis (IONS) enters into an agreement to develop precision genetic drugs

Ionis (IONS) enters into an agreement to develop precision genetic drugs

Ionis Pharmaceuticals, Inc. IONS announced that it has entered into a collaboration with a private California-based gene editing company, Metagenomi, to add gene editing to its extensive technology platform. With this partnership, the companies seek to leverage Ionis’ expertise in RNA-targeted therapies with Metagenomi’s next-generation gene editing systems to develop novel gene targets. Initially, the …

Ionis (IONS) enters into an agreement to develop precision genetic drugs Read More »

Whole Metagenome Analysis Helps Identify Depressive Gut Microbe

Whole Metagenome Analysis Helps Identify Depressive Gut Microbe

In a three-year study, researchers from Skoltech, the RAS Vavilov Institute of General Genetics, Moscow Mental Health Clinic No. 1 named after NA Alexeev, and the Federal Medical Research Center of Psychiatry and Serbsky’s Narcology examined how gut microbes in patients with major depressive disorder are different from those in mentally healthy people. After analyzing …

Whole Metagenome Analysis Helps Identify Depressive Gut Microbe Read More »

Researchers provide new insight into the frustrating process that makes HIV stealth

Researchers provide new insight into the frustrating process that makes HIV stealth

An immune response that likely evolved to help fight infections appears to be the mechanism that pushes the human immunodeficiency virus (HIV) into a latent state, hiding in cells to burst out again, Duke Health researchers report. . Publication on November 14 in the journal Natural microbiologythe research team provides new insights into the vexing …

Researchers provide new insight into the frustrating process that makes HIV stealth Read More »

New approach may help design shorter, more powerful trials to evaluate drugs for Parkinson's disease

New approach may help design shorter, more powerful trials to evaluate drugs for Parkinson’s disease

Testing whether a new drug has an impact on the progression of Parkinson’s disease takes years, in part because the disease often progresses very slowly. Many patients with Parkinson’s disease experience no worsening of their symptoms during a typical clinical trial, even without treatment. Now Scripps Research scientists have developed a tool that analyzes genetic …

New approach may help design shorter, more powerful trials to evaluate drugs for Parkinson’s disease Read More »